Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Generation of lymphokine-activated killer cells in long-term cultures.

Literature DB >> 2210801

Generation of lymphokine-activated killer cells in long-term cultures.

Abstract

The induction of lymphokine-activated killer (LAK) cells with low levels of interleukin-2 (IL-2) was studied in long-term cultures with regard to the relationship between cytotoxicity and proliferation. Proliferation of LAK cells reduced their cytolytic activity, which was restored when proliferation stagnated. In order to explain this phenomenon, a competition between receptors of intermediate and high affinity for IL-2 is suggested. Whereas the former type of receptor mediates cytotoxicity, the second one seems to be responsible exclusively for proliferation of LAK cells.

Entities: Disease Gene

Mesh：

Substances：
Interleukin-2

Year: 1990 PMID： 2210801 PMCID： PMC1384236

Source DB: PubMed Journal: Immunology ISSN： 0019-2805 Impact factor: 7.397

18 in total

1. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors: M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal: Proc Natl Acad Sci U S A Date: 1986-12 Impact factor: 11.205

2. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors: R J Robb; C M Rusk; J Yodoi; W C Greene
Journal: Proc Natl Acad Sci U S A Date: 1987-04 Impact factor: 11.205

3. A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors.

Authors: M Dukovich; Y Wano; P Katz; B R Cullen; J H Kehrl; W C Greene
Journal: Nature Date: 1987 Jun 11-17 Impact factor: 49.962

4. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.

Authors: T Morita; Y Yonese; N Minato
Journal: J Natl Cancer Inst Date: 1987-03 Impact factor: 13.506

Review 5. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.

Authors: E A Grimm
Journal: Biochim Biophys Acta Date: 1986-12-17

6. Generation of lymphokine-activated killer cells does not require DNA synthesis.

Authors: M Malkovský; M Jíra; J Madar; V Malkovska; B Loveland; G L Asherson
Journal: Immunology Date: 1987-03 Impact factor: 7.397

7. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors: S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal: N Engl J Med Date: 1987-04-09 Impact factor: 91.245

8. Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Authors: L M Muul; E P Director; C L Hyatt; S A Rosenberg
Journal: J Immunol Methods Date: 1986-04-17 Impact factor: 2.303

9. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors: J H Phillips; L L Lanier
Journal: J Exp Med Date: 1986-09-01 Impact factor: 14.307

3. The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs.

Authors: S K Obukhov; M J Gennie; A L Tutt; J T Kemshead; H B Coakham; P C Beverely
Journal: J Neurooncol Date: 1992-07 Impact factor: 4.130

3 in total